Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients
Giampà E, Di Bonito M, Ferretti V, Nuvoli G, Paoletti F, Piazzini M, Ranieri M, Tuveri MA, Vinicola V
Minerva endocrinologica · 5 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2020-01-01 · Minerva Endocrinol · vol. 44 · número 4 · págs. 344–350
- Editorial
- Edizioni Minerva Medica
- Citado
- 6 citas · más que el 63% de estudios similares · 0.7× el promedio de su campo
- Referencias
- 30 trabajos
- Acceso
- De pago
- Áreas de investigación
- Bone health and osteoporosis research · Vitamin D Research Studies · Bone health and treatments
- Palabras clave
- Medicine, Calcifediol, Vitamin D and neurology, Internal medicine, Osteoporosis, Cholecalciferol, Osteopenia, Alendronic acid, Gastroenterology, Population, vitamin D deficiency, Vitamin, Bone remodeling, Bisphosphonate, Endocrinology, Urology, Bone mineral
- MeSH
- femur, lumbar vertebrae, humans, osteoporosis, postmenopausal, calcium, phosphorus, alendronate, cholecalciferol, calcifediol, parathyroid hormone, alkaline phosphatase, vitamin d, osteocalcin, drug therapy, combination, exercise, retrospective studies, bone density, aged, middle aged, female, bone density conservation agents
9 autores
- Emiliano Giampà🇦🇱Academy of Sciences of Albania; Albanian University
- Mario Di Bonito
- Valentino Ferretti
- Giuseppe Nuvoli🇮🇹University of Sassari
- Franco Paoletti
- Marco Piazzini
- Mauro Ranieri
- M A Tuveri🇮🇹Fondazione Centro Marino Internazionale
- Vincenzo Vinicola🇺🇸🇮🇹Bone Health and Osteoporosis Foundation; Fondazione Santa Lucia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Several formulations of vitamin D and alendronate are available for the treatment of osteoporosis. The objective of this study was to examine efficacy and safety of calcifediol (25(OH)D) compared to cholecalciferol (vitamin D3) and also the relationship between different formulations of alendronate and adverse reactions.
Methods
We observed a population of women diagnosed with postmenopausal osteoporosis or osteopenia treated with alendronate 70 mg weekly associated to vitamin D3 or 25(OH)D at monthly total dose of 625 µg. Data collected both at baseline (T0) and at follow-up after at least 12 months of therapy (T1) were: demographic characteristics, BMI, full medical history, lumbar T-score, femur T-score, calcium, osteocalcin, alkaline phosphatase, PTH and vitamin D blood level.
Results
A total of 362 patients were enrolled in the study. Alendronate 70 mg + calcifediol (A+25(OH)D) group consisted of 202 patients while 160 patients were treated with alendronate 70 mg + cholecalciferol (A+D3). In the A+25(OH)D group, we observed a significant increase in lumbar T-score value (0.26±0.35 vs. 0.13±0.3) and serum vitamin D (20.64±20.71 vs. 6.07±7.61 ng/mL) levels compared to the A+D3 group (P<0.05). The lowest incidence of gastrointestinal adverse reactions was observed among patients taking alendronate 70 mg in drinkable solution form (P<0.05).
Conclusions
Alendronate 70 mg with calcifediol gives a better outcome in the treatment of osteoporosis according to lumbar T-score and vitamin D serum level observed at one-year follow-up compared to alendronate 70 mg with cholecalciferol. Both vitamin D formulations did not show to cause hypercalcemia in this study. Alendronate 70 mg in drinkable solution form is also associated with lowest incidence of gastrointestinal adverse reactions.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.